Zelniker TA, Raz I, Sabatine MS, Wiviott SD, et al. Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial". Circulation 2020;142:e129-e130.
PMID: 32897752